VV
VV5.F Vext Science Inc
- Market cap
- EUR 32.2M
- P/E
- -
- P/B
- 0.62x
- ROE
- -4.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is VV5.F undervalued?
Graham numberThe Graham number of Vext Science Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Vext Science Inc fundamental analysis
No fundamental analysis for Vext Science Inc yet.
Vext Science Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Vext Science Inc
Vext Science, Inc., through its subsidiaries, engages in integrated cannabis operations in the United States. It owns and manages cultivation facilities, manufacturing units, and dispensaries; and involves in the cultivation, extraction, manufacture, and sale of THC and CBD cartridges, concentrates, edibles, and extracts. The company also engages in the retail dispensary activities; and wholesale distribution of cannabis THC and hemp CBD products under the Vapen, Pure Touch,…
Full company profileVext Science Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Vext Science Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 14.8M | 18.5M | 22.3M | 25.2M | 37.2M | 35.4M | 34.8M | 36.0M | 51.4M | 48.6M |
| Gross Profit | 8.25M | 9.17M | 9.37M | 9.90M | 16.4M | 23.1M | 12.0M | 8.98M | 14.5M | 24.5M |
| Operating Income | 5.72M | 5.63M | 3.58M | 3.23M | 9.21M | 9.28M | -7.84M | -11.2M | -6.94M | 1.58M |
| EBITDA | 6.13M | 5.51M | 4.57M | 5.40M | 12.3M | 15.2M | 16.8M | -2.02M | 5.14M | 18.0M |
| Net Income | 4.11M | 3.75M | 2.79M | 2.13M | 4.99M | 10.9M | 4.40M | -22.4M | -18.0M | -2.41M |
| EPS | 0.22 | 0.20 | 0.12 | 0.04 | 0.07 | 0.13 | 0.03 | -0.09 | -0.07 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 13.8M | 23.4M | 38.8M | 55.5M | 83.7M | 121M | 150M | 137M | 121M | 117M |
| Total Liabilities | 5.07M | 6.43M | 13.1M | 19.1M | 24.3M | 48.6M | 54.6M | 61.2M | 65.2M | 63.0M |
| Shareholders' Equity | 8.77M | 17.0M | 25.7M | 36.3M | 59.4M | 71.9M | 95.0M | 75.7M | 55.4M | 54.2M |
| Cash & Short-term Investments | 0.00 | 3.39M | 7.29M | 1.75M | 6.47M | 5.93M | 8.72M | 4.62M | 5.08M | 4.54M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 1.87M | 2.41M | -393K | 3.10M | 11.7M | 5.92M | 4.42M | 3.29M | 11.7M | 5.59M |
| Capital Expenditure | 1.13M | 1.50M | 5.26M | 4.06M | 18.8M | 8.86M | 2.74M | 1.47M | 3.57M | 3.69M |
| Free Cash Flow | 737K | 907K | -5.65M | -965K | -7.10M | -2.94M | 1.69M | 1.82M | 8.15M | 1.90M |
| Ratios | ||||||||||
| ROE | 46.8% | 22.0% | 10.9% | 5.9% | 8.4% | 15.2% | 4.6% | -29.6% | -32.5% | -4.5% |
| ROA | 29.7% | 16.0% | 7.2% | 3.8% | 6.0% | 9.1% | 2.9% | -16.4% | -14.9% | -2.1% |
| Net Profit Margin | 27.7% | 20.3% | 12.5% | 8.4% | 13.4% | 30.8% | 12.6% | -62.3% | -35.0% | -5.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Vext Science Inc dividends
Vext Science Inc has not paid dividends in the last 9 fiscal years.
Who owns Vext Science Inc
- Insiders 45.69%
- Institutions 0.49%
- Public & others 53.82%
- Shares outstanding 186M
- Free float 102M
Vext Science Inc company profile
- Company name
- Vext Science Inc
- Ticker
- VV5.F
- ISIN
- CA9255401064
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 4152 North, Phoenix, AZ, United States, 85019
- Phone
- 604 688 9588
- Website
- vextscience.com
About Vext Science Inc
Vext Science, Inc., through its subsidiaries, engages in integrated cannabis operations in the United States. It owns and manages cultivation facilities, manufacturing units, and dispensaries; and involves in the cultivation, extraction, manufacture, and sale of THC and CBD cartridges, concentrates, edibles, and extracts. The company also engages in the retail dispensary activities; and wholesale distribution of cannabis THC and hemp CBD products under the Vapen, Pure Touch, Appalachian Pharm, Herbal Wellness, Prism, Firebrand, and Revibe brands. The company was formerly known as Vapen MJ Ventures Corporation and changed its name to Vext Science, Inc. in November 2019. Vext Science, Inc. was incorporated in 2015 and is headquartered in Phoenix, Arizona.
Vext Science Inc management
5- Mr. Eric J. OffenbergerCEO, COO, President & Director
- Mr. Jason Thai NguyenFounder & Director
- Mr. Trevor SmithChief Financial Officer
- Mr. Scott EverettGeneral Counsel & Corporate Secretary
- Jonathan RossInvestor Relations Officer